Telix Competitors

Pink Sheets . USA . 
Stock . Telix Pharmaceuticals Limited
TLPPF Stock  USD 14.10  0.30  2.08%   
Telix Pharmaceuticals competes with Genscript Biotech, Keros Therapeutics, Zentalis Pharmaceuticals, MAIA Biotechnology, and Nautilus Biotechnology; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Telix Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Telix Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Telix Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Telix Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
10.1514.1018.05
Details
Intrinsic
Valuation
LowRealHigh
7.6911.6415.59
Details
Naive
Forecast
LowNextHigh
9.2713.2217.17
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
13.8914.4214.95
Details

Telix Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Telix Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Telix and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Telix Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ACLX
+ 0.81
KROS
NAUT
+ 0.56
IVBXF
MAIA
+ 0.35
GNNSF
NAUT
+ 0.32
MAIA
MAIA
+ 0.26
ZNTL
ACLX
+ 0.26
ZNTL
  
High negative correlations   
IVBXF
- 0.37
GNNSF
ACLX
- 0.33
IVBXF
ACLX
- 0.29
MAIA
NAUT
- 0.27
GNNSF
IVBXF
- 0.25
ZNTL
KROS
- 0.25
GNNSF

Risk-Adjusted Indicators

There is a big difference between Telix Pink Sheet performing well and Telix Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Telix Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GNNSF  0.76 (0.20) 0.00  1.60  0.00 
 0.00 
 0.00 
(0.72)
 18.45 
KROS  2.10  0.18  0.09  0.24  2.17 
(2.31)
 4.39 
(4.31)
 16.94 
ZNTL  4.13  0.13  0.01  0.41  5.21 
(4.39)
 11.41 
(8.64)
 33.76 
IVBXF  1.88  0.01  0.00  0.12  0.00 
 0.00 
 5.48 
(7.81)
 24.34 
MAIA  3.96 (0.48) 0.00 (0.55) 0.00 
 0.00 
 8.37 
(9.23)
 28.10 
GRPH  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ROIVW  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
FTHWF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
NAUT  2.95 (0.39) 0.00 (0.04) 0.00 
 0.00 
 6.02 
(6.50)
 17.43 
ACLX  2.39  0.30  0.08  0.53  2.81 
(2.60)
 6.28 
(5.68)
 15.13 
All Fundamental Data

Telix Pharmaceuticals Competitive Analysis

The better you understand Telix Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Telix Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Telix Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TLPPF GNNSF KROS ZNTL IVBXF MAIA GRPH ROIVW FTHWF NAUT
 2.08 
 14.10 
Telix
 0.72 
 1.38 
Genscript
 3.86 
 55.92 
Keros
 1.57 
 3.23 
Zentalis
 4.72 
 4.85 
Innovent
 3.26 
 2.08 
MAIA
 1.84 
 2.67 
Graphite
 11.84 
 2.68 
Roivant
 0.00 
 0.04 
Field
 0.84 
 2.40 
Nautilus
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Very risky
Very steady
Somewhat reliable
Relatively risky
Unstable
Very steady
Very steady
Very steady
Risky
Market Performance
(90 Days Performance)
Insignificant
Very Weak
OK
Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Quite High
Low
Low
About Average
Average
Very High
Dangerous
Dangerous
Dangerous
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Not Rated
Not Rated
Not Rated
Sell
Current Ratio
3.21
2.92
14.39
9.61
3.21
2.78
27.07
9.84
N/A
49.75
Net Asset
109.81 M
2.23 B
370.02 M
551.69 M
16.24 B
7.57 M
188.46 M
2.39 B
N/A
305.56 M
Profit Margin
N/A
-0.66
N/A
N/A
-0.68
N/A
N/A
N/A
N/A
N/A
EBITDA
(70.07 M)
(494 M)
(152.18 M)
(275.5 M)
(2.99 B)
(20.18 M)
(70.7 M)
(1.11 B)
N/A
(74.3 M)
Operating Margin
-3.95
-0.64
-151.18
-5.16
-0.78
N/A
N/A
-37.08
N/A
N/A
Current Valuation
1.39 B
5.11 B
1.67 B
(124.17 M)
5.13 B
45.77 M
1.88 M
N/A
19.22 M
189.8 M
Price To Book
21.16
6.65
4.09
0.64
4.22
33.65
1.01
N/A
N/A
1.34
Retained Earnings
N/A
N/A
(381.43 M)
(888.56 M)
N/A
(63.98 M)
(367.05 M)
(3.77 B)
N/A
(202.24 M)
Current Asset
N/A
N/A
11.95 M
N/A
N/A
N/A
8 K
N/A
N/A
N/A
Beta
2.31
1.35
1.24
1.74
0.16
0.34
0.2
N/A
N/A
1.04
Number Of Employees
11
5.57 K
160
124
5.54 K
13
6
620
8
161
Shares Outstanding
317.02 M
2.12 B
40.51 M
71.27 M
1.53 B
25.33 M
58.24 M
N/A
89.88 M
125.56 M
Cash Flow From Operations
(59.33 M)
(136.79 M)
(124.51 M)
(207.82 M)
(2.02 B)
(13.07 M)
(90.01 M)
(843.39 M)
N/A
(51.71 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
0.3
N/A
N/A
N/A
Total Debt
2.57 M
121.07 M
14.44 M
43.15 M
2.02 B
7.09 M
362 K
481.4 M
N/A
34.63 M
Return On Equity
-1.55
-0.56
-0.44
-0.43
-0.29
-5.6
-0.52
N/A
N/A
-0.28
Z Score
N/A
33.0
N/A
N/A
2.4
N/A
N/A
-2.95
N/A
N/A
Return On Asset
-0.41
-0.12
-0.28
-0.25
-0.14
-1.07
-0.18
N/A
N/A
-0.18
Book Value Per Share
0.34
0.36
13.57
4.98
6.54
0.028
3.17
7.74
N/A
1.78
Number Of Shares Shorted
N/A
N/A
2.41 M
7.05 M
N/A
662.41 K
704.04 K
215.84 K
N/A
1.21 M
Current Liabilities
N/A
N/A
5.72 M
N/A
N/A
N/A
451 K
N/A
N/A
N/A
Total Asset
109.81 M
2.23 B
370.02 M
551.69 M
16.24 B
7.57 M
188.46 M
2.39 B
N/A
305.56 M
Debt To Equity
0.024
0.56
0.003
0.099
0.29
N/A
0.024
0.13
N/A
0.087
Short Ratio
N/A
N/A
7.8
5.49
N/A
10.99
7.93
N/A
N/A
19.69
Target Price
N/A
N/A
90.69
9.5
N/A
12.63
7.0
N/A
N/A
3.56
Shares Owned By Institutions
13.59
24.68
94.6
98.18
44.34
7.5
84.4
N/A
22.41
50.22
Market Capitalization
1.44 B
6.67 B
2.18 B
226.62 M
8.37 B
54.46 M
189.84 M
N/A
6.96 M
298.84 M
Price To Earning
N/A
200.0
N/A
N/A
N/A
N/A
0.7
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
-0.08
N/A
N/A
N/A
Price To Sales
52.21
10.82
3350.11
5.59
1.39
N/A
N/A
N/A
N/A
N/A
Net Income
(80.51 M)
(347.87 M)
(152.99 M)
(292.19 M)
(3.14 B)
(19.77 M)
(124.65 M)
(1.12 B)
N/A
(63.67 M)
Earnings Per Share
-0.2
-0.17
-5.22
-2.5
-0.32
-1.34
-2.19
-4.09
N/A
-0.56
Shares Owned By Insiders
27.6
38.31
5.4
3.46
7.15
17.49
9.17
N/A
22.99
33.46
Revenue
4.9 M
510.6 M
151 K
N/A
4.27 B
N/A
N/A
61.28 M
N/A
N/A
Working Capital
N/A
N/A
322.92 M
427.35 M
N/A
2.63 M
183.22 M
1.53 B
N/A
167.72 M
Cash And Equivalents
122.61 M
1.26 B
215.62 M
455.22 M
8.32 B
8.15 M
322.29 M
2 B
N/A
299.34 M
Cash Per Share
0.39
0.6
8.37
7.99
5.67
0.75
5.54
8.97
N/A
2.4
Gross Profit
5.05 M
303.48 M
(87.27 M)
N/A
2.98 B
N/A
N/A
N/A
N/A
N/A
Day Typical Price
14.1
1.38
55.44
3.24
4.85
2.12
2.69
2.79
0.0412
2.43
Accumulation Distribution
N/A
N/A
0.0745
0.0994
N/A
0.0633
0.0364
0.13
N/A
0.048
Market Facilitation Index
N/A
N/A
4.27
0.34
N/A
0.14
0.1
0.39
N/A
0.12
Daily Balance Of Power
(9,223,372,036,855)
(9,223,372,036,855)
0.4871
0.1471
(9,223,372,036,855)
(0.50)
(0.50)
(0.92)
0.0
0.1667
Period Momentum Indicator
(0.30)
(0.01)
2.08
0.05
(0.24)
(0.07)
(0.05)
(0.36)
N/A
0.02
Rate Of Daily Change
0.98
0.99
1.04
1.02
0.95
0.97
0.98
0.88
1.0
1.01
Day Median Price
14.1
1.38
55.2
3.25
4.85
2.14
2.7
2.85
0.0412
2.44
Price Action Indicator
(0.15)
(0.01)
1.77
0.005
(0.12)
(0.1)
(0.06)
(0.34)
N/A
(0.03)
Relative Strength Index
42.29
N/A
67.08
21.88
1.32
24.74
17.17
58.9
N/A
18.68
Coefficient Of Variation
1931.95
(995.45)
768.73
3108.58
(2,781)
(1,337)
N/A
N/A
N/A
(4,869)
Mean Deviation
2.94
0.7645
2.1
4.13
1.88
3.96
N/A
N/A
N/A
2.95
Jensen Alpha
0.1399
(0.20)
0.179
0.1254
0.0068
(0.48)
N/A
N/A
N/A
(0.39)
Total Risk Alpha
(0.43)
(0.55)
(0.09)
(0.74)
(0.74)
(1.21)
N/A
N/A
N/A
(0.69)
Sortino Ratio
0.0187
N/A
0.094
0.0104
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
15.56
N/A
6.15
30.17
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
3.95
2.1
2.8
5.84
3.79
5.17
N/A
N/A
N/A
3.79
Kurtosis
2.35
18.63
2.18
2.31
4.46
0.7729
N/A
N/A
N/A
0.1861
Potential Upside
5.78
N/A
4.39
11.41
5.48
8.37
N/A
N/A
N/A
6.02
Treynor Ratio
0.4301
1.6
0.2445
0.4099
0.1154
(0.55)
N/A
N/A
N/A
(0.04)
Maximum Drawdown
18.38
18.45
16.94
33.76
24.34
28.1
N/A
N/A
N/A
17.43
Variance
15.62
4.39
7.82
34.06
14.37
26.72
N/A
N/A
N/A
14.38
Market Risk Adjusted Performance
0.4401
1.61
0.2545
0.4199
0.1254
(0.54)
N/A
N/A
N/A
(0.03)
Risk Adjusted Performance
0.0478
(0.07)
0.107
0.0334
(0.02)
(0.05)
N/A
N/A
N/A
(0.01)
Skewness
(0.29)
(3.08)
0.6345
0.7617
(0.1)
0.265
N/A
N/A
N/A
0.0137
Semi Deviation
3.73
N/A
2.17
5.21
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
0.0187
(0.16)
0.0833
0.0098
(0.07)
(0.10)
N/A
N/A
N/A
(0.06)
Value At Risk
(5.49)
(0.72)
(4.31)
(8.64)
(7.81)
(9.23)
N/A
N/A
N/A
(6.50)
Expected Short fall
(3.24)
N/A
(2.31)
(4.39)
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
3.94
N/A
2.48
5.49
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
13.94
N/A
4.69
27.15
N/A
N/A
N/A
N/A
N/A
N/A

Telix Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Telix Pharmaceuticals Competition

Telix Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Telix Pharmaceuticals in relation to its competition. Telix Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Telix Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Telix Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Telix Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Telix Pharmaceuticals position

In addition to having Telix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Furniture Thematic Idea Now

Furniture
Furniture Theme
Companies producing and selling home and office furniture. The Furniture theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Telix Pink Sheet

When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:
How To Invest In Telix
Details
Is Telix Pink Sheet a good investment?
Details
What is Telix Pharmaceuticals' Net Worth?
Details
Largest Pharmaceutical Products Companies
View
Largest Biotechnology Companies
View
Check out Telix Pharmaceuticals Correlation with its peers.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Telix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY